# Clinical Trials Data BRAF - Document 3

# S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01693419

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Pathologically confirmed locally advanced unresectable, recurrent or metastatic adenocarcinoma of pancreas (Stage III-IV ; TNM staging system)\n\* Measurable or evaluable disease by RECIST criteria 1.1\n\* Minimum age of 18 years\n\* ECOG Performance status 0-1\n\* Prior adjuvant chemotherapy without gemcitabine, erlotinib or S-1 is allowed if more than 4 weeks elapsed since completion of chemotherapy.\n\* More than 4 weeks since completion of prior radiotherapy (measurable or evaluable lesions should be outside the radiation field)\n\* Adequate organ functions\n\* Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital.\n\nExclusion Criteria:\n\n\* Patients treated previously with gemcitabine, erlotinib, or S-1 as adjuvant chemotherapy.\n\* Patients with CNS metastases\n\* Patients with active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus, myocardial infarction during the preceding 6 months, pregnancy, or breast feeding\n\* Any previous or concurrent malignancy other than non-melanoma skin cancer or in situ cancer of uterine cervix\n\* Known history of cerebral or leptomeningeal metastases or neurologic disease",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
The eligibility criteria for this clinical trial, as listed, do not mention anything about a BRAF gene mutation. The inclusion and exclusion criteria focus on the type and stage of cancer, previous treatments, organ function, age, performance status, and certain other health conditions.  
  
Based on the provided information, a BRAF gene mutation is neither mentioned as a criterion for inclusion nor as one for exclusion. Therefore, a patient with a BRAF gene mutation would not be automatically excluded or included based solely on that mutation. However, other eligibility criteria, such as the specific cancer type and previous treatments, would need to be met.  
  
It would be best to consult with the clinical trial coordinators or a healthcare provider to confirm eligibility, as they may have more comprehensive criteria or additional information not detailed in the brief description provided.